Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2

Future Medicinal Chemistry

Volumn 6, Issue 16, 2014, Pages 1771-1789

  Ding, Chao ^a   Zhang, Cunlong ^a,b   Zhang, Mingli ^a   Chen, Yu Zong ^b   Tan, Chunyan ^a   Tan, Ying ^a   Jiang, Yuyang ^a,c  

^a TSINGHUA UNIVERSITY   (China)

^b Shenzhen Kivita Innovative Drug Discovery Institute   (China)

^c Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; AXITINIB; BMS 690514; BRIVANIB; CABOZANTINIB; CEDIRANIB; CHIR 265; DOVITINIB; FORETINIB; GOLVATINIB; HISTONE DEACETYLASE INHIBITOR; LENVATINIB; LINIFANIB; LUCITANIB; MGCD 265; MOTESANIB; NINTEDANIB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; REGORAFENIB; SORAFENIB; SUNITINIB; TELATINIB; TIVOZANIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 2; MOLECULAR LIBRARY;

CANCER INHIBITION; CLINICAL TRIAL (TOPIC); DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; HISTONE ACETYLATION; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PHARMACOLOGY; POLYPHARMACOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; POLYPHARMACOLOGY; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84911867552     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.112     Document Type: Review

References (166)

1. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 21(2), 140-146 (2009
2. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9(1), 28-39 (2009
3. Levitzki A. Tyrosine kinase inhibitors views of selectivity, sensitivity, and clinical performance. Ann. Rev. Pharmacol. Toxicol. 53, 161-185 (2013
4. Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. Mechanisms of drug combinations interaction and network perspectives. Nat. Rev. Drug Discov. 8(2), 111-128 (2009
5. Hanahan D. Rethinking the war on cancer. Lancet 383(9916), 558-563 (2013
6. Hopkins AL. Network pharmacology the next paradigm in drug discovery. Nat. Chem. Bio. 4(11), 682-690 (2008
7. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006
8. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30(7), 679-692 (2012
9. Costantino L, Barlocco D. Challenges in the design of multitarget drugs against multifactorial pathologies a new life for medicinal chemistry? Future Med. Chem. 5(1), 5-7 (2013
10. Peters JU. Polypharmacology-foe or friend? J. Med. Chem. 56(22), 8955-8971 (2013
11. Rosini M. Polypharmacology the rise of multitarget drugs over combination therapies. Future Med. Chem. 6(5), 485-487 (2014
12. Musumeci F, Radi M, Brullo C, Schenone S. Vascular endothelial growth factor (VEGF) receptors drugs and new inhibitors. J. Med. Chem. 55(24), 10797-10822 (2012
13. Ellis LM, Hicklin DJ. VEGF-Targeted therapy: mechanisms of anti-Tumour activity. Nat. Rev. Cancer 8(8), 579-591 (2008
14. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl Acad. Sci. USA 94(14), 7192-7197 (1997
15. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4-25 (1997
16. Shibuya M. Structure and function of VEGF/VEGFreceptor system involved in angiogenesis. Cell Struct. Funct. 26(1), 25-35 (2001
17. Stuttfeld E, Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life 61(9), 915-922 (2009
18. Wang JF, Zhang X, Groopman JE. Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J. Biol. Chem. 279(26), 27088-27097 (2004
19. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 12(17), 5018-5022 (2006
20. Dayanir V, Meyer RD, Lashkari K, Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J. Biol. Chem. 276(21), 17686-17692 (2001
21. Lamalice L, Houle F, Jourdan G, Huot J Phosphorylation of Tyrosine 1214 on VEGFR2 Is Required for VEGF-induced Activation of Cdc42 Upstream of SAPK2/p38. Oncogene 23(2), 434-445 (2004
22. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15(18), 2169-2177 (1997
23. Zhang C, Tan C, Ding H, Xin T, Jiang Y. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials. Curr. Pharm. Des. 18(20), 2921-2935 (2012
24. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 66(6), 3197-3204 (2006
25. Sini P, Wyder L, Schnell C, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin. Cancer Res. 11(12), 4521-4532 (2005
26. Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 15(10), 3484-3494 (2009
27. Poindessous V, Ouaret D, El Ouadrani K, et al. EGFRand VEGF (R)-Targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin. Cancer Res. 17(20), 6522-6530 (2011
28. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28(5), 767-772 (2010
29. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer a randomized, double-blind Phase III trial. J. Clin. Oncol. 30(2), 134-141 (2012
30. Rodríguez-Antona C, Pallares J, Montero-Conde C, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr. Relat. Cancer 17(1), 7-16 (2010
31. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC) a double-blind, randomised, Phase 3 trial. Lancet Oncol. 11(7), 619-626 (2010
32. Reardon DA, Conrad CA, Cloughesy T, et al. Phase I study of AEE788, a novel multitarget inhibitor of ErbBand VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother. Pharmacol. 69(6), 1507-1518 (2012
33. Baselga J, Mita AC, Schöffski P, et al. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development a Phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. Clin. Cancer Res. 18(22), 6364-6372 (2012
34. Soria JC, Baselga J, Hanna N, et al. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and-4 and VEGFR-1 to-3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur. J. Cancer 49(8), 1815-1824 (2013
35. Chow LQ, Jonker DI, Dy GK, et al. A Phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies. Cancer Chemother. Pharmacol. 71(5), 1273-1285 (2013
36. Gherardi E, Birchmeier W, Birchmeier C, Woude GV. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12(2), 89-103 (2012
37. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 19(10), 542-551 (2009
38. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10(11), 760-774 (2010
39. Puri N, Khramtsov A, Ahmed S, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67(8), 3529-3534 (2007
40. Sulpice E, Ding S, Muscatelli-Groux B, et al. Cross-Talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol. Cell 101(9), 525-539 (2009
41. Cui JJ. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J. Med. Chem. 57(11), 4427-4453 (2013
42. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31(29), 3639-3646 (2013
43. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29(19), 2660-2666 (2011
44. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer results of a Phase II randomized discontinuation trial. J. Clin. Oncol. 31(4), 412-419 (2013
45. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31(2), 181-186 (2013
46. Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE 8(3), e54014 (2013
47. Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G Jr. Phase II trial of single-Agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest. New Drugs 31(2), 417-424 (2013
48. Shapiro GI, Mccallum S, Adams LM, et al. A Phase 1 doseescalation study of the safety and pharmacokinetics of oncedaily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest. New Drugs 31(3), 742-750 (2013
49. Wang W, Li Q, Takeuchi S, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin. Cancer Res. 18(6), 1663-1671 (2012
50. Takeuchi S, Wang W, Li Q, et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFRTKI resistance in EGFR mutant lung cancer. Am. J. Pathol 181(3), 1034-1043 (2012
51. Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol. Cancer Ther. 11(10), 2149-2157 (2012
52. Besterman JM, Fournel M, Dupont I, Bonfils C, Dubay M, Ste-Croix H. Potent preclinical anti-Tumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in Phase II clinical development, in combination with taxanes or erlotinib. J. Clin. Oncol. 28(Suppl.), e13595 (2010). Abstract
53. Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol. Sci. 33(10), 531-541 (2012
54. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22(4), 201-207 (2001
55. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res. 17(19), 6130-6139 (2011
56. Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonylsubstituted indolinone (BIBF 1120). J. Med. Chem. 52(14), 4466-4480 (2009
57. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1) a Phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15(2), 143-145 ( 2014
58. Rolfo C, Raez LE, Bronte G, et al. BIBF 1120/nintedanib a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin. Investig. Drugs 22(8), 1081-1088 (2013
59. Rashdan S, Hanna N. Nintedanib for the treatment of nonsmall-cell lung cancer. Expert. Opin. Pharmacother. 15(5), 729-739 (2014
60. Majem M, Pallarès C. An update on molecularly targeted therapies in second-And third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-Angiogenic agents. Clin. Transl. Oncol. 15(5), 343-357 (2013
61. Ball DW, Sherman SI, Jarzab B, et al. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC) cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J. Clin. Oncol. 30(15), 5518 (2012
62. Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid 23(4), 392-407 (2013
63. Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-Tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 340(1), 97-103 (2013
64. Johnson PJ, Qin S, Park J-W, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma. Results from the randomized Phase III BRISK-FL study. J. Clin. Oncol. 31(28), 3517-3524 (2013
65. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed results from the randomized Phase III BRISK-PS Study. J. Clin. Oncol. 31(28), 3509-3516 (2013
66. Sivanand S, Peña-Llopis S, Zhao H, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med. 4(137), 137-175 (2012
67. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma an open-label, randomised Phase 3 trial. Lancet Oncol. 15(3), 286-296 (2014
68. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J. Clin. Oncol. 31(26), 3212-3218 (2013
69. Hoff PM, Hochhaus A, Pestalozzi BC, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer a randomized, double-blind, Phase III study (HORIZON II). J. Clin. Oncol. 30(29), 3596-3603 (2012
70. Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer a double-blind, randomized Phase III study (HORIZON III). J. Clin. Oncol. 30(29), 3588-3595 (2012
71. Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J. Clin. Oncol. 31(18), 2296-2302 (2013
72. Bello E, Colella G, Scarlato V, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 71(4), 1396-1405 (2011
73. Bello E, Taraboletti G, Colella G, et al. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol. Cancer Ther. 12(2), 131-140 (2013
74. Hellstrom M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14), 3047-3055 (1999
75. Edling CE, Hallberg B. c-Kit-A hematopoietic cell essential receptor tyrosine kinase. Int. J. Biochem. Cell Biol. 39(11), 1995-1998 (2007
76. Christensen J. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-Angiogenic and antitumour activities. Ann. Oncol. 18(Suppl. 10), X3-X10 (2007
77. Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW. The multi-Targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46(3), 283-291 (2004
78. Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol. Cancer Ther. 5(5), 1280-1289 (2006
79. Motzer R, Hutson T, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-Alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 24(Suppl. 18), S2 (2006
80. Casali P, Garrett C, Blackstein M, et al. Updated results from a Phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J. Clin. Oncol. 24(Suppl. 18), 9513 (2006
81. Demetri GD, Van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib a randomised controlled trial. Lancet 368(9544), 1329-1338 (2006
82. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 501-513 (2011
83. Deeks ED, Raymond E. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors. BioDrugs 25(5), 307-316 (2011
84. Blumenthal GM, Cortazar P, Zhang JJ, et al. FDA approval summary sunitinib for the treatment of progressive welldifferentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 17(8), 1108-1113 (2012
85. Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renalcell carcinoma a randomised open-label Phase 3 trial. Lancet Oncol. 14(13), 1287-1294 (2013
86. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma overall survival analysis and updated results from a randomised Phase 3 trial. Lancet Oncol. 14(6), 552-562 (2013
87. Cella D, Escudier B, Rini B, et al. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma Phase III (AXIS) trial. Br. J. Cancer 108(8), 1571-1578 (2013
88. I Rini B, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) a randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011
89. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma. Results from a Phase III trial. J. Clin. Oncol. 31(30), 3791-3799 (2013
90. Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a Phase II randomized discontinuation trial in patients with renal cell carcinoma. J. Clin. Oncol. 30(14), 1678-1685 (2012
91. Wolpin BM, Ng K, Zhu AX, et al. Multicenter Phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 18(4), 377-378 (2013
92. Toh HC, Chen PJ, Carr BI, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119(2), 380-387 (2013
93. Toh H, Chen P, Carr B, et al. Linifanib Phase II trial in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 28(15S), 4038 (2010
94. Chiu Y-L, Carlson DM, Pradhan RS, Ricker JL. Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma. Clin. Ther. 35(11), 1770-1777 (2013
95. Strumberg D, Schultheis B, Adamietz I, et al. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br. J. Cancer 99(10), 1579-1585 (2008
96. Eskens FA, Steeghs N, Verweij J, et al. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, plateletderived growth factor receptor β, and c-Kit, in patients with advanced or metastatic solid tumors. J. Clin. Oncol. 27(25), 4169-4176 (2009
97. Ko A, Tabernero J, De Paredes MG, et al. Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEJ). J. Clin. Oncol. 28(Suppl.), E1455 (2010). Abstract
98. Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind Phase III study of Motesanib plus Carboplatin/Paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer MONET1. J. Clin. Oncol. 30(23), 2829-2836 (2012
99. Martin M, Roche H, Pinter T, et al. Motesanib, or openlabel bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer a Phase 2, randomised, doubleblind, placebo-controlled study. Lancet Oncol. 12(4), 369-376 (2011
100. Miyamoto N, Sakai N, Hirayama T, et al. Discovery of N-[5-({2-[(cyclopropylcarbonyl) amino] imidazo [1, 2-b] pyridazin-6-yl}oxy)-2-methylphenyl]-1, 3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor. Bioorg. Med. Chem. 21(8), 2333-2345 (2013
101. Awazu Y, Mizutani A, Nagase Y, et al. Anti-Angiogenic and anti-Tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and plateletderived growth factor receptor tyrosine kinase. Cancer Sci. 104(4), 486-494 (2013
102. Roberts P, Der C. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26(22), 3291-3310 (2007
103. Bollag G, Tsai J, Zhang J, et al. Vemurafenib the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 11(11), 873-886 (2012
104. Piscazzi A, Costantino E, Maddalena F, et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 97(6), E898-E906 (2012
105. Fecteau J-F, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol. Med. 18(1), 19 (2012
106. Lang SA, Schachtschneider P, Moser C, et al. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol. Cancer Ther. 7(11), 3509-3518 (2008
107. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 23(Suppl. 16), S380 ( 2005
108. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007
109. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008
110. Bruix J, Raoul J-L, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma subanalyses of a Phase III trial. J. Hepatol. 57(4), 821-829 (2012
111. Thomas L, Lai SY, Dong W, et al. Sorafenib in metastatic thyroid cancer a systematic review. Oncologist 19(3), 251-258 (2014
112. Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision a double-blind, randomized, placebocontrolled Phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 11(1), 349 (2011
113. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129(1), 245-255 (2011
114. Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303-312 (2013
115. Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 295-302 (2013
116. George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib a multicenter Phase II trial. J. Clin. Oncol. 30(19), 2401-2407 (2012
117. Bruix J, Tak W-Y, Gasbarrini A, et al. Regorafenib as secondline therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, Phase II safety study. Eur. J. Cancer 49(16), 3412-3419 (2013
118. Ramurthy S, Subramanian S, Aikawa M, et al. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J. Med. Chem. 51(22), 7049-7052 (2008
119. Garcia-Gomez A, Ocio EM, Pandiella A, San Miguel JF, Garayoa M. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest. New Drugs 31(1), 200-205 (2013
120. Su Y, Vilgelm AE, Kelley MC, et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res. 18(8), 2184-2198 (2012
121. Zambon A, Niculescu-Duvaz I, Niculescu-Duvaz D, Marais R, Springer CJ. Small molecule inhibitors of BRAF in clinical trials. Bioorg. Med. Chem. Lett. 22(2), 789-792 (2012
122. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009
123. Banerjee S, Mehta S, Haque I, et al. VEGF-A165 induces human aortic smooth muscle cell migration by activating Neuropilin-1-VEGFR1-PI3K Axis. Biochemistry 47(11), 3345-3351 (2008
124. Ruan GX, Kazlauskas A. Axl is essential for VEGF-Adependent activation of PI3K/Akt. EMBO J. 31(7), 1692-1703 (2012
125. Zhao YW, Jin L, Li ZM, Zhao CJ, Wei YQ, Yang HS. Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during antiangiogenesis therapy. Cancer Sci. 102(8), 1469-1475 (2011
126. Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Bio. 4(11), 691-699 (2008
127. Brown A, Shi Q, Moore TW, et al. Monocarbonyl curcumin analogues heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties. J. Med. Chem. 56(9), 3456-3466 (2013
128. Taby R, Issa JP. Cancer epigenetics. CA Cancer J. Clin. 60(6), 376-392 (2010
129. Robey RW, Chakraborty AR, Basseville A, et al. Histone deacetylase inhibitors emerging mechanisms of resistance. Mol. Pharm. 8(6), 2021-2031 (2011
130. Scroggins BT, Robzyk K, Wang D, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 25(1), 151-159 (2007
131. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5(10), 761-772 (2005
132. Kaluza D, Kroll J, Gesierich S, et al. Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin. EMBO J. 30(20), 4142-4156 (2011
133. Qian DZ, Wang X, Kachhap SK, et al The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 64(18), 6626-6634 (2004
134. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12(2), 634-642 (2006
135. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 280(2), 145-153 (2009
136. Yu C, Friday BB, Lai J-P, et al. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin. Cancer Res. 13(4), 1140-1148 (2007
137. Jane EP, Premkumar DR, Addo-Yobo SO, Pollack IF. Abrogation of mitogen-Activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. J. Pharmacol. Exp. Ther. 331(1), 327-337 (2009
138. Curis Inc.: US20080234332 (2008
139. Curis Inc.: US20090076044 (2009
140. Curis Inc.: US007928136 (2011
141. Chipscreen Biosciences Ltd.: US20090298886 (2009
142. Chipscreen Biosciences Ltd.: WO10139180 (2010
143. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347), 298-307 (2011
144. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin. 60(4), 222-243 (2010
145. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 6(10), 569-579 (2009
146. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-Targeted therapy. Clin. Cancer Res. 14(20), 6371-6375 (2008
147. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 15(24), 7471-7478 (2009
148. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J. Clin. Oncol. 30(32), 4026-4034 (2012
149. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006
150. Bergers G, Hanahan D. Modes of resistance to anti-Angiogenic therapy. Nat. Rev. Cancer 8(8), 592-603 (2008
151. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3), 232-239 (2009
152. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220-231 (2009
153. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8(4), 210-221 (2011
154. Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT. Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep. 3(2), 277-281 (2013
155. Marusyk A, Almendro V, Polyak K. Intra-Tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 12(5), 323-334 (2012
156. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17(3), 320-329 (2011
157. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 133(3421), 571-573 (1889
158. Mcmillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12(3), 217-228 (2013
159. Azmi AS, Mohammad RM. Rectifying cancer drug discovery through network pharmacology. Future Med. Chem. 6(5), 529-539 (2014
160. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10(2), 130-137 (2010
161. Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 73(16), 4965-4977 (2013
162. Chung AS, Wu X, Zhuang G, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-Angiogenic therapy. Nat. Med. 19(9), 1114-1123 (2013
163. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21(3), 283-296 (2012
164. Sessa C, Guibal A, Del Conte G, Rüegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat. Clin. Prac. Oncol. 5(7), 378-391 (2008
165. Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy-evolving view based on clinical trial results. Nat. Rev. Clin. Oncol. 9(5), 297-303 (2012
166. Kerbel RS, Kamen BA. The anti-Angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4(6), 423-436 (2004